A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...
We are pleased to recognize four outstanding students who have recently completed their thesis projects with us at IDL Diagnostics. The projects started in January 2025. Putri Rezqita and Yu Shi from Karolinska Institutet contributed their deep knowledge in health and...
Last week, IDL Diagnostics participated in the Sweden-Indonesia Sustainability Partnership (SISP) 2025, organized by Business Sweden and the Swedish Embassy in Indonesia. The Sweden-Indonesia Sustainability Partnership (SISP) is a platform designed to foster...
We attended the European Association of Urology #EAU25 in Madrid last weekend. Many valuable insights and great discussion with urologists from all over the world on the latest urology practice and how our products can contribute in improving cancer care. #EAU25 is...
AroCell participated at Redeye's Technology & Life Science day on December 3rd. CEO Anders Hultman presented the latest developments and future prospects of the company. The presentation is now available for listening below. AroCell: CEO Anders Hultman presenterar...
Arocell recently participated as an exhibitor at the Medica trade fair, joining 5,800 other exhibitors from 72 countries. Medica showcases modern healthcare solutions for both outpatients and inpatients, making it a pivotal event in the medical industry. We engaged in...
A delegation from Airlangga University and Dr. Soetomo General Hospital visited the AroCell/IDL Biotech office in Stockholm on Tuesday, 18th of June. The Indonesian Embassy in Sweden facilitated the meeting. Airlangga University, one of the oldest medical schools in...
Last week AroCell participated in three major events across the medical and research domains. From Paris to San Diego and Copenhagen, our team presented the latest advancements and interacted with industry and scientific leaders in the field. EAU Congress 2024 In...
A recent study investigated the use of urine-based biomarkers, including UBC Rapid, to monitor high-risk non-muscle invasive bladder cancer patients. The purpose of the study was to discover new applications for these biomarkers in order to safely reduce the frequency...
We are happy to announce that two abstracts on clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at the American Association of Cancer Research 2024 (AACR 2024) held from April 5 to 10 in San Diego, USA. One of the abstracts is...
